The Russian clinical trial market accounts for a significant share in the global clinical trial market. The country has got the population and the prevalence of diseases which cater as a good pool of subjects for conducting the studies. The high quality of the regulations followed in the Russian market for clinical trials has led to better optimization of the studies. The Russian clinical trials market enjoys high speed of conducting studies owing to the high patient recruitment rates. The number of clinical trials conducted in Russia by foreign sponsors has tripled in the last decade. The quality of the clinical trials in Russia has been accepted by regulatory agencies such as the FDA and the EMA. The FDA inspection has rated Russia as having a standard quality of investigators leading to low deficiency rate. Russia has caught the attraction of big players in the pharmaceuticals industry, which has led to huge investments by these companies.
There has been an exponential rise in the clinical research services outsourced to Russia in recent years. Despite the economic downturn, outsourcing trends in the field of clinical trials continue to be on a high in Russia. The value of the clinical trials market in Russia was around US$ 200 Million in 2012. Owing to various factors like a huge population base, easy patient recruitment and cheaper cost of trials, which are currently driving the market, it is expected that by 2016, the clinical trials market would surpass US$ 300 million mark.
“Russia Clinical Trial Market Opportunity Analysis” research report by KuicK Research is an intriguing text that gives detailed facts and analysis on latest developments in the Russia Clinical Trial Market. Report discusses various segments of the clinical trial market and analyzes the factors responsible for the growth and the need to resolve challenges to maintain growth momentum in future. Report discusses following aspects related to booming Clinical Trial Market in Russia: